Natco Pharma net profit slips 35pc to Rs 104 crore in Q3
New Delhi: Drug firm Natco Pharma on Wednesday reported a 34.46 per cent drop in consolidated net profit to Rs 104.4 crore for the quarter ended December 2019.
The company had posted a net profit of Rs 159.3 crore for the corresponding period of the previous fiscal, Natco Pharma said in a filing to BSE.
Consolidated total income stood at Rs 513 crore for the quarter under consideration. It was Rs 580 crore for the same period a year ago.
"The company continues to face margin pressures in its Hepatitis C portfolio," the filing said.
The company's board has recommended a third interim dividend of Rs 3.50 per equity share of Rs 2 each.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd